Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)'s stock had its "buy" rating reaffirmed by Chardan Capital in a report released on Tuesday,Benzinga reports. They currently have a $55.00 target price on the biopharmaceutical company's stock. Chardan Capital's price objective points to a potential upside of 86.00% from the stock's previous close.
A number of other research firms have also commented on XENE. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $67.00 price objective for the company. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. The Goldman Sachs Group reduced their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, Needham & Company LLC reduced their price objective on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.82.
Read Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Stock Performance
Shares of NASDAQ:XENE traded down $0.17 during trading hours on Tuesday, hitting $29.57. 1,147,831 shares of the company's stock traded hands, compared to its average volume of 508,722. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00. The company's fifty day simple moving average is $34.19 and its two-hundred day simple moving average is $38.03. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -10.49 and a beta of 1.21.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.07. The business had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same quarter last year, the business posted ($0.62) EPS. On average, analysts anticipate that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.
Institutional Trading of Xenon Pharmaceuticals
A number of hedge funds have recently made changes to their positions in XENE. FMR LLC increased its holdings in Xenon Pharmaceuticals by 8.8% in the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock worth $294,991,000 after buying an additional 607,606 shares during the last quarter. Boxer Capital Management LLC acquired a new position in Xenon Pharmaceuticals in the fourth quarter worth approximately $23,520,000. Vestal Point Capital LP increased its holdings in Xenon Pharmaceuticals by 60.5% in the first quarter. Vestal Point Capital LP now owns 1,300,000 shares of the biopharmaceutical company's stock worth $43,615,000 after buying an additional 490,000 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Xenon Pharmaceuticals by 38.9% in the fourth quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company's stock worth $53,190,000 after buying an additional 380,112 shares during the last quarter. Finally, Stempoint Capital LP acquired a new position in Xenon Pharmaceuticals in the fourth quarter worth approximately $14,733,000. 95.45% of the stock is owned by hedge funds and other institutional investors.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
